April 12, 2018 / 10:39 AM / 7 months ago

BRIEF-Prometic Presents New PBI-4050 Clinical Data From Ongoing Alström Syndrome Phase 2 Trial

April 12 (Reuters) - Prometic Life Sciences Inc:

* PROMETIC PRESENTS NEW PBI-4050 CLINICAL DATA FROM ONGOING ALSTRöM SYNDROME PHASE 2 TRIAL

* PBI-4050 DECREASED INSULIN RESISTANCE IN LIVER

* FAT BIOPSIES FURTHER DEMONSTRATE PBI-4050 CLINICAL ACTIVITY

* CLINICAL ACTIVITY AND TOLERABILITY OF PBI-4050 WERE SUSTAINED WITH PROLONGED TREATMENT Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below